Navigation Links
S1 Pharmaceuticals Appoints Robert Taylor Segraves, MD, PhD, and Robert Pyke, MD, PhD to Its Scientific Advisory Board

JERSEY CITY, N.J., Oct. 24, 2011 /PRNewswire/ -- S1 Pharmaceuticals, Inc. (S1) today announced that it has appointed Robert Taylor Segraves, MD, PhD, and Robert Pyke, MD, PhD to its Scientific Advisory Board.  Dr. Segraves and Dr. Pyke will help guide the clinical development of S1's lead product, Lorexys, as it prepares for Phase I clinical trials.

"We are pleased to be able to attract such knowledgeable and prominent individuals as Segraves and Pyke to participate as members of our Scientific Advisory Board," stated Nicolas G. Sitchon, MA, MBA, Chief Executive Officer of S1 Pharmaceuticals.  "The formation of a distinguished advisory board to provide medical, clinical, and strategic guidance to the Company marks the next step in the evolution of our Lorexys clinical development program."

Dr. Segraves is a professor of psychiatry at Case Western Reserve School of Medicine.  Among his scientific interests are the treatment of sexual disorders, the co-morbidity of sexual dysfunction with anxiety and depressive disorders, sexual side effects of pharmacological agents, and pharmacotherapy of sexual disorders.  Dr. Segraves has authored over 200 publications in the area of human sexuality, numerous international presentations, and five texts.  He sits on the editorial board of the International Journal of Impotence Research and is the current editor of the Journal of Sex and Marital Therapy.  Dr. Segraves obtained his M.D. from Vanderbilt University, his PhD from the University of London, and completed his residency in psychiatry at the University of Chicago.

Dr. Pyke served as Director of Clinical Research at Boehringer Ingelheim Pharmaceuticals where he led the Flibanserin Worldwide premenopausal HSDD clinical program that ended in October 2010.  Dr. Pyke has a distinguished career of leading drug after drug to FDA approval with Parke-Davis, Bristol-Myers Squibb, and Upjohn.  He has continued his clinical practice treating anxiety, depression, and substance abuse.  Dr. Pyke is a member of numerous societies, including the International Society for the Study of Women's Sexual Health.  He completed his Ph.D. at the University of Wisconsin, Madison, obtained his M.D. at the University of Miami, and completed his medical training in Internal Medicine at the University of Michigan.

"I look forward to serving on the advisory board for this promising potential therapy," stated Pyke. "The field of sexual health is ever evolving and it's exciting to join a company that is on the leading edge of this evolution."

About S1 Pharmaceuticals, Inc.
S1 is an early-stage biopharmaceutical company developing therapeutic solutions for disorders of Women's Sexual Health.  The most common type of Female Sexual Dysfunction (FSD) is a loss of libido and lack of sexual interest known as Hypoactive Sexual Desire Disorder (HSDD).  S1 is developing its lead product, Lorexys, as an oral drug and will seek to demonstrate that Lorexys can be the first safe and effective treatment approved by the FDA for HSDD in women.

(201) 839-0941

SOURCE S1 Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Valeant Pharmaceuticals to Announce 2011 Third Quarter Results on November 3, 2011
2. Cumberland Pharmaceuticals Ranks as one of the Fastest Growing Companies in North America on Deloittes 2011 Technology Fast 500™
3. Onyx Pharmaceuticals Announces Third Quarter 2011 Financial Results Teleconference and Webcast
4. Jazz Pharmaceuticals Announces Third Quarter 2011 Results Conference Call on November 1
5. Arrien Pharmaceuticals Appoints Dr. Philip LoGrasso to its Scientific Advisory Board for CNS/Neurodegenerative Diseases
6. Critical Alerts For Intel, Mosaic, Deckers, Foot Locker, and Jazz Pharmaceuticals Released By Seven Summits Research
7. Pacira Pharmaceuticals, Inc. Announces New Data Demonstrating Longer Time to First Opioid Use and Reduction in Opioid-Related Adverse Events With EXPAREL™ Compared to Bupivacaine HCl
8. Amylin Pharmaceuticals Reports Third Quarter Financial Results
9. CureFAKtor Pharmaceuticals to Present at 10th Annual BIO Investor Forum
10. ADVENTRX Pharmaceuticals to Present at the 10th Annual BIOInvestor Forum Conference on October 26
11. Rock Creek Pharmaceuticals Announces Expanded International Shipping Options for Anatabloc™, Physician Conferences on Anatabine Research
Post Your Comments:
(Date:6/24/2016)... 24, 2016 The Academy of Managed Care ... that would allow biopharmaceutical companies to more easily ... make formulary and coverage decisions, a move that addresses ... medicines. The recommendations address restrictions in the ... the drug label, a prohibition that hinders decision makers ...
(Date:6/24/2016)... and SAN CLEMENTE, Calif. , June ... -based mobile pulmonary function testing company, is now able to ... devices developed by ndd Medical Technologies , Inc. ... done in hospital-based labs.  Thanks to ndd,s EasyOne PRO ® , ... , can get any needed testing done in the comfort of ...
(Date:6/24/2016)... According to a new market ... Needles, Safety Pen Needles), Needle Length (4mm, 5mm, 6mm, ... of Purchase (Retail, Non-Retail) - Trends & Global Forecasts ... market for the forecast period of 2016 to 2021. ... by 2021 from USD 1.65 Billion in 2016, growing ...
Breaking Medicine Technology:
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... "FCPX editors ... customizable inside of Final Cut Pro X," said Christina Austin - CEO of Pixel ... style. Final Cut Pro X users can now reveal the media of ...
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in cancer ... they remain in the eye of the beholder, according to experts who offered insights ... American Journal of Managed Care. For the full issue, click here . , ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many women ... diagnosed with endometriosis. These women need a treatment plan to not only alleviate ... that can help for preservation of fertility and ultimately achieving a pregnancy. The ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , the largest ... as the Medical Director of its new Mesquite-Samuell Farm facility. , “We are ... Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency ...
(Date:6/24/2016)... Los Angeles, CA (PRWEB) , ... June 24, 2016 , ... ... plastic surgery procedures that most people are unfamiliar with. The article goes on to ... known procedures, but also many of these less common operations such as calf and ...
Breaking Medicine News(10 mins):